Navigation Links
Major Breakthrough in Hepatitis C Vaccine Development
Date:8/13/2012

MELBOURNE, Australia, Aug. 13, 2012 /PRNewswire/ -- Researchers at the Burnet Institute have solved a hepatitis C vaccine mystery which, once developed could be the first ever preventative vaccine for the virus.

Currently undergoing formal preclinical studies, the vaccine is the result of breakthrough work done by Associate Professor Heidi Drummer with her team from the Institute's Centre for Virology.

Hepatitis C affects around 200 million people around the world - a preventative vaccine has the potential to have a significant global health impact.

Associate Professor Drummer and her team have overcome a major hurdle in HCV vaccine research, developing a vaccine candidate that protects against a number of different HCV strains.

"Hepatitis C has a great ability to change its structure and evade the immune response. This makes vaccine development challenging," Associate Professor Drummer said.

"Our vaccine is unique as it contains only the most essential, conserved parts of the major viral surface protein, eliciting antibodies that prevent both closely and distantly related hepatitis C viruses from entering cells, thereby preventing infection."

Associate Professor Drummer unveiled the details about her HCV vaccine project at the prestigious Immunotherapeutics and Vaccine Summit (ImVacS) in Cambridge, Massachussets on August 13.

To arrange an interview with Associate Professor Heidi Drummer please contact:
Catherine Somerville
Media and Communications Officer
Burnet Institute
Tel: +61-(0)-422-043-498 or
Email: cathsomerville@burnet.edu.au


'/>"/>
SOURCE Burnet Institute
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
2. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
7. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
8. Misonix Exhibits at Major Worldwide Spine Conference
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Aribex Reaches Major Milestone, Builds 10,000th NOMAD Handheld X-ray
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... chief financial officer, is scheduled to present a company overview ... in Las Vegas on Tuesday, May 10th at 10:00 a.m. ... The presentation will be webcast live and can be accessed ...
... May 5, 2011 Rochester Medical Corporation (NASDAQ: ... ended March 31, 2011. The Company reported record ... for the second quarter of last year.  It also reported ... to net loss of ($351,000) or ($0.03) per diluted share ...
Cached Medicine Technology:Rochester Medical Reports Second Quarter Results 2Rochester Medical Reports Second Quarter Results 3Rochester Medical Reports Second Quarter Results 4Rochester Medical Reports Second Quarter Results 5Rochester Medical Reports Second Quarter Results 6Rochester Medical Reports Second Quarter Results 7Rochester Medical Reports Second Quarter Results 8Rochester Medical Reports Second Quarter Results 9Rochester Medical Reports Second Quarter Results 10
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
... The PalmScan A2000 A-Scan [i.e., PalmScan A2000] ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, and ... the axial length (AL), anterior,chamber depth (ACD), ... This PalmScan A2000,device is also intended for ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: